Altered expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the formation of chronic Brucellosis

Thumbnail Image

Date

2016-07-31

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Hindawi

Abstract

Brucellosis is a zoonotic disease that is still endemic in developing countries. Despite early diagnosis and treatment of patients, chronic infections are seen in 10-30% of patients. In this study, we aimed to investigate the immunological factors that play roles in the transition of brucellosis from acute infection into chronic infection. Here, more than 2000 miRNAs were screened in peripheral blood mononuclear cells (PBMCs) of patients with acute or chronic brucellosis and healthy controls by using miRNA array, and the results of the miRNA array were validated through qRT-PCR. Findings were evaluated using GeneSpring GX (Agilent) 13.0 software and KEGG pathway analysis. Four miRNAs were expressed in the chronic group but were not expressed in acute and control groups. Among these miRNAs, the expression level of miR-1238-3p was increased while miR-494, miR-6069, and miR-1393p were decreased (p< 0.05, fold change > 2). These miRNAs have the potential to be markers for chronic cases. The differentially expressed miRNAs and their predicted target genes involved in endocytosis, regulation of actin cytoskeleton, MAPK signaling pathway, and cytokine-cytokine receptor interaction and its chemokine signaling pathway indicate their potential roles in chronic brucellosis and its progression. It is the first study of miRNA expression analysis of human PBMC to clarify the mechanism of inveteracy in brucellosis.

Description

Keywords

Immunology, Dendritic cell maturation, B-virus infection, Microrna expression, Gene-expression, Up-regulation, Integrated analysis, Abortus invasion, Down-regulation, Cancer cells, TNF-alpha

Citation

Budak, F. vd. (2016). "Altered expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the formation of chronic Brucellosis". Journal of Immunology Research, 2016, 1-11.